Safety Information
| Description | Publish Date | LINKS |
|---|---|---|
| Salbutamol pMDI, Advisory Letter | 30/09/2025 |  |
| Tafenoquine: A radical cure for P. vivax malaria | 10/01/2025 | |
Important safety information on Amoxicillin / Amoxicillin and clavulanic acid containing products in Ethiopia |
09/09/2023 |  |
| Important safety information on Dolutegravir in Ethiopia (Safety Notification_Korean label update for Dolutegravir containing products) | 01-11-2023 | |
| Important safety information on Topical Corticosteroids containing products in Ethiopia | 15-11-2023 | |
| Important safety information on Hepatitis B surface antigen recombinant vaccine in Ethiopia (Initial Safety Notification Engerix-B and Myelitis_November 2023) | 17-11-2023 | |
| Important safety information on Hepatitis B surface antigen recombinant vaccine in Ethiopia (Updated Safety Notification Engerix-B and Myelitis_December 2023) | 02-01-2024 | |
Important safety information on Hepatitis B surface antigen recombinant vaccine (Updated Safety Notification Engerix-B and Myelitis_January 2024) |
08/01/2024 |
|
| Important safety information on Amoxycillin/clavulanate containing products - Amendments to the instructions for medical use of medicines containing amoxicillin/clavulanate, Ukrainian HA website | 29/02/2024 |
|
Important safety information on Abacavir containing products - Regarding amendments to the instructions for medical use of medicines containing abacavir |
19/03/2024 |
|
Important safety information on Hepatitis B surface antigen recombinant vaccine - Updated Safety Notification Engerix-B and Myelitis_May 2024 |
07/05/2024 |
|
